CagrilintideInterpret the evidence
Why REIMAGINE 2 compared cagrilintide with semaglutide
2 numbered sourcesSource years 2025, 2026
Short chains of amino acids connected by peptide bonds are peptides. Some activate receptors and change how the body handles a meal. Cagrilintide is an investigational long-acting peptide modeled on amylin. Semaglutide acts on the GLP-1 receptor. REIMAGINE 2 studied the two peptides alone and together in people with type 2 diabetes and overweight or obesity. Its main question was how much adding cagrilintide to semaglutide changed a blood sugar measure. [1, 2]
This 2026 report described a randomized trial of 2,713 adults whose blood sugar remained above target while taking metformin, sometimes with an SGLT2 inhibitor. The investigators used an active comparison with semaglutide as well as placebo and a cagrilintide-only arm. The active comparison is important because semaglutide already affects blood glucose. A comparison with placebo would tell readers how the two-peptide product performed against an inactive treatment. Comparing the product with semaglutide can help isolate the added effect of including cagrilintide in the tested combination. [1]
The primary outcome was the change in glycated hemoglobin, or HbA1c, over 68 weeks. HbA1c reflects how much glucose has attached to hemoglobin in red blood cells and summarizes blood sugar exposure over the preceding months. For the principal comparison, the average estimated HbA1c changes were −1.91 percentage points with the combination and −1.75 with semaglutide alone. The estimated difference was −0.16 percentage points. The reported interval around that estimate excluded zero, while the size of the difference shows the scale of the additional effect in this trial. [1]
The research group also recorded adverse events. Gastrointestinal problems were the most common events with active treatment. About 87% in the main combination group reported an adverse event, compared with about 81% in the corresponding semaglutide group and 82% in the cagrilintide-only group. Those totals count participants who reported at least one event. They do not describe the severity, persistence or cause of each event. [1]
The main result concerns a defined fixed combination in a population already receiving particular diabetes medicines. Having a cagrilintide-only arm adds information about the component, but the main numerical contrast estimates the added change when cagrilintide is included with semaglutide. The trial also followed people for a specified interval and measured HbA1c. It did not directly measure outcomes such as long-term kidney complications for the purpose of that comparison. The estimates and adverse-event observations provide separate pieces of evidence about the tested regimens. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.John B. Buse et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. The Lancet Diabetes & Endocrinology (publication 2026-06-07). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
